MBRX · Moleculin Biotech, Inc.

Moleculin Biotech announced the issuance of a Hong Kong patent (No. 40073244) covering its proprietary method of reconstituting liposomal Annamycin, extending protection through June 25, 2040. The patent is jointly owned with The University of Texas System and adds to an expanding global IP portfolio that includes allowed or granted patents in the United States, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, and Taiwan. This strategic move strengthens the company's long-term exclusivity for Annamycin, its lead asset, ahead of the expected release of first Phase 3 clinical data later this quarter. Annamycin is designed to avoid cardiotoxicity and multidrug resistance, targeting relapsed/refractory AML and soft tissue sarcoma lung metastases. The patent positions Moleculin in the Asian market, a fast-growing region for cancer therapeutics.